Sales income at ₹15,184 crore grew 10.1%. Global Innovative Medicines sales at $351 million grew 12.8% accounting for 21.9% of sales.
| Photo Credit: FRANCIS MASCARENHAS
Sun Pharmaceuticals Industries Ltd. for the first quarter ended June 30, 2026 reported a 27% year-n-year growth in consolidated net profit to ₹2,895 crore.Sales income at ₹15,184 crore grew 10.1%. Global Innovative Medicines sales at $351 million grew 12.8% accounting for 21.9% of sales.Kirti Ganorkar, Managing Director, Sun Pharma said, “Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions.” “Recent semaglutide approvals in India, Brazil and South Africa underscore our capabilities in developing complex peptide products for patients globally. Organon shareholders have approved the proposed acquisition by Sun, which is on track to close in early 2027,” he added.Formulation sales in India were ₹5,475 crore, registering a growth of 16%. India Formulation sales accounted for 36.1% of total consolidated sales, the company said.Formulation sales in the U.S. were $427 million, lower by 9.7%. “Innovative Medicines continued to grow, partially offsetting the decline in generics business. U.S. sales accounted for approximately 26.6% of total consolidated sales,” the company said.Emerging Markets formulations sales were $311 million, up by 4.2% and accounted for 19.4% of total consolidated sales.Rest of World (ROW) Formulations sales were $218 million and accounted for 13.6% of total consolidated sales, the company said. While Global Innovative Medicines sales were $351 million for Q1FY27, up 12.8% and accounted for 21.9% of sales, external sales of Active Pharmaceutical Ingredients (API) were ₹597 crore, up 10.5%. Published - July 31, 2026 08:14 pm IST
